BLRX supply chain intelligence for BioLineRx Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
BioLineRx Ltd. (BLRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOKINE-THERAPEUTICS-LTD | BIOKINE-THERAPEUTICS-LTD | 85% | In 2012, we in-licensed the rights to motixafortide under a license agreement from Biokine. |
| HEMISPHERIAN | HEMISPHERIAN | 80% | In 2025, we entered into a Collaboration Agreement with Hemispherian for the development of GLIX1 via Tetragon. |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from BLRX graph: rsuant to the terms of a supply agreement to be negotiated in good faith with Bellerophon. See “— Out-Licensing Agreem… |
| ABT | Abbott Laboratories | 72% | rsuant to the terms of a supply agreement to be negotiated in good faith with Bellerophon. See “— Out-Licensing Agreement with Bellerophon.” There can be no assurance that our therapeutic candidates,… |
| CGEN | Compugen Ltd. | 72% | Reciprocal relationship from CGEN graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from CGEN graph: se estimates under different assumptions or conditions. Revenue Recognition … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | rsuant to the terms of a supply agreement to be negotiated in good faith with Bellerophon. See “— Out-Licensing Agreement with Bellerophon.” There can be no assurance that our therapeutic candidates,… |
| MRK | Merck & Co., Inc. | 72% | quent autologous transplantation in patients with multiple myeloma. Following this approval, we commenced commercialization of motixafortide in the U.S. independently, as planned, in order to acceler… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from BLRX graph: quent autologous transplantation in patients with multiple myeloma. Following this approval, we commenced commercializ… |
| ONCY | Oncolytics Biotech Inc. | 72% | anufacture drug products for our current clinical trials or, if we choose to do so, commercialize therapeutic candidates ourselves. The suppliers of the drug substances used for our current clinical … |
| ONCY | Oncolytics Biotech Inc. | 72% | Reciprocal relationship from ONCY graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from ONCY graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from ONCY g… |
| PRGO | Perrigo Company plc | 72% | ction 404 is complicated and time-consuming. Furthermore, as our business continues to grow both domestically and internationally, our internal controls will become more complex and will require sign… |
| PRGO | Perrigo Company plc | 72% | Reciprocal relationship from PRGO graph: Reciprocal relationship from BLRX graph: ction 404 is complicated and time-consuming. Furthermore, as our business continues to grow both domestically and int… |
| PRRUF | PRRUF | 72% | Reciprocal relationship from PRRUF graph: . 28 Table of Contents IMP761 Preclinical Development On January 3, 2017 we announced a new early stage product candidate to be known as IMP761, developed in… |
| SNYNF | Sanofi | 72% | rsuant to the terms of a supply agreement to be negotiated in good faith with Bellerophon. See “— Out-Licensing Agreement with Bellerophon.” There can be no assurance that our therapeutic candidates,… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from SNYN… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AYRMID | AYRMID | 90% | we and Ayrmid entered into a transition services agreement pursuant to which we agreed to provide Ayrmid with certain services related to the development and commercialization of motixafortide within… |
| HONG-SENG-TECHNOLOGY-LIMITED | HONG-SENG-TECHNOLOGY-LIMITED | 90% | On August 27, 2023, we entered into the Gloria License Agreement, with Hong Seng Technology Limited, or HST, and Gloria, and/or with HST, the Gloria Licensee, pursuant to which we granted HST an excl… |
| HST | Host Hotels & Resorts, Inc. | 90% | Reciprocal relationship from HST graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from HST graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from HST grap… |
| ABT | Abbott Laboratories | 72% | required to make under our in-licensing agreements is comprised of various components that are paid commensurate with the progressive development and commercialization of our drug products. Our in-li… |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from ABT graph: Reciprocal relationship from BLRX graph: required to make under our in-licensi… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from BLRX graph: required to make under our in-licensi… |
| JNJ | Johnson & Johnson | 72% | required to make under our in-licensing agreements is comprised of various components that are paid commensurate with the progressive development and commercialization of our drug products. Our in-li… |
| MRK | Merck & Co., Inc. | 72% | quent autologous transplantation in patients with multiple myeloma. Following this approval, we commenced commercialization of motixafortide in the U.S. independently, as planned, in order to acceler… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from BLRX graph: quent autologous transplantation in patients with multiple myeloma. Following this approval, we commenced commercializ… |
| ONCY | Oncolytics Biotech Inc. | 72% | our ability to build brand identity and possibly leading to customer confusion. 57 Manufacturing Our laboratories are located in our headquarters in Modi’in, Israel, and are in part compliant with FD… |
| ONCY | Oncolytics Biotech Inc. | 72% | Reciprocal relationship from ONCY graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from ONCY graph: Reciprocal relationship from BLRX graph: our ability to build brand identity… |
| PRGO | Perrigo Company plc | 72% | Reciprocal relationship from PRGO graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from PRGO graph: Reciprocal relationship from BLRX graph: tion with the in-licensing of BL-80… |
| PRGO | Perrigo Company plc | 72% | tion with the in-licensing of BL-8040 from Biokine, and as a condition to OCS consent to the transaction, we agreed to abide by any obligations resulting from funds previously received by Biokine fro… |
| PRRUF | PRRUF | 72% | Reciprocal relationship from PRRUF graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from PRRUF graph: . 28 Table of Contents IMP761 Preclinical Development On January 3, 2017 w… |
| SNYNF | Sanofi | 72% | required to make under our in-licensing agreements is comprised of various components that are paid commensurate with the progressive development and commercialization of our drug products. Our in-li… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX graph: required to make under our in-licensing agreements is comprised of various components that are paid commensurate wit… |
| AYRMID-PHARMA-LTD | AYRMID-PHARMA-LTD | 62% | icensed product in this indication. Licensing rights for other indications and related support were deemed immaterial. F - 48 BioLineRx Ltd. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS NOTE 15 – L… |
| LABORATORIES-LTD-TEVA-PHARMACEUTICALS-USA-INC | LABORATORIES-LTD-TEVA-PHARMACEUTICALS-USA-INC | 62% | imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| MEITHEAL-PHARMACEUTICALS-INC | MEITHEAL-PHARMACEUTICALS-INC | 62% | imilar marks or try to prevent us from using our marks, consequently impeding our ability to build brand identity and possibly leading to customer confusion. 48 Manufacturing With respect to GLIX1, w… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BLRX-DEBT | Debt stack $9.1M | 90% | Market cache reports total debt of $9.1M. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| BMRN | BioMarin Pharmaceutical Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| GRDX | GridAI Technologies Corp. | 100.00 | 2 | |
| ADAG | Adagene Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| FBRX | Forte Biosciences, Inc. | 100.00 | 2 |